Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Jonathan C. Song, Peter J. McDonnell, Erlinda M. Gordon, Frederick L. Hall, W. French Anderson

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)306-309
Number of pages4
JournalHuman gene therapy
Volume14
Issue number3
StatePublished - Feb 10 2003

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this